FDA's CBD Stalemate and the State Novel Food Niche

Photo by CBD-Infos-com via Pixabay.

Picture a founder of a CBD sparkling water brand. She has a clean certificate of analysis from an accredited lab, a distributor ready to place an order, and no regulator who will tell her whether the can can legally be sold as a food or beverage. She can phone FDA and get a general statement. She cannot get a yes.

The thesis of this piece is simple. Where FDA will not write rules, states and consultants write the working rulebook. Food regulation has seen that before, and the people who understood the gap early were paid for it.

A caution before going further. Several 2025-2026 details here, including the federal hemp redefinition, its effective date and individual state rules, were not verified when this was drafted. Treat them as leads. Confirm each against congress.gov, fda.gov and the relevant state agency sites before relying on any of it.

The Gap FDA Left Open

Photo by Edyttka1388 via Pixabay.

Start with what is established. The 2018 Farm Bill removed hemp from the Controlled Substances Act. It did not touch FDA's authority over food, dietary supplements and drugs, and that second half is the part the CBD industry keeps relearning.

The same year, FDA approved Epidiolex, a CBD-based drug. Under the drug exclusion clause of the Federal Food, Drug, and Cosmetic Act (section 301(ll)), an ingredient that was first approved as a drug, or substantially investigated as one, generally cannot be added to food or sold as a supplement. That clause is the core legal reason CBD is treated as unlawful in food and supplements.

In January 2023, FDA said its existing food and supplement pathways were not suitable for CBD and that it would work with Congress on a new approach. I have not confirmed whether anything on fda.gov has changed since, so check the agency's CBD page directly.

FDA has sent warning letters to CBD sellers over disease claims and food use. What it has not done is set a legal threshold or a safe-intake level. A seller can be told that a product is a problem without anyone saying what a compliant product looks like.

Here is the reasoned extrapolation. A stall this long reads as a pattern rather than an accident. Federal food-ingredient questions that need a statutory fix have a habit of sitting for years while the agency waits for Congress, and Congress waits for a consensus nobody has built. If that holds, the gap is not a temporary glitch. It is the operating environment for the mid-term, and a gap that persists is a place where services get sold.

The Hemp Redefinition Cliff

Photo by Nora Topicals via Pexels.

This section rests on leads I could not verify, so read it as a checklist. I recall that the FY2026 agriculture appropriations package, enacted around November 2025, narrowed the federal hemp definition to exclude many intoxicating and synthesized cannabinoid products. I also recall an effective date roughly a year later, reportedly around November 2026.

Do not repeat any of that as fact until you have read the statutory text on congress.gov. Specifically confirm the exact language, any total THC limit per container, and how CBD itself is treated. Also check whether bills to delay the effective date or to create a CBD framework are pending, and cite them only by verified bill number.

What follows is reasoned extrapolation. Any hard compliance date does the same thing to a market. Brands that ignored the issue suddenly ask their lawyers, their lab and their distributors what is still legal. That wave of questions is the demand driver for advisory work, and it tends to arrive in the months before a deadline rather than after it.

The counter-case is real. Congress could delay the date, soften the language or attach a CBD framework that changes the picture entirely. Delays of compliance dates are common in federal law, and industry groups have strong incentives to lobby for one. If the cliff moves, the urgency window shrinks.

So the business case should not hang on one date. A deadline is a good sales hook, but a consultancy that only exists to answer one deadline is a project shop with an expiry date. The sturdier bet is that the question will remain unsettled for years, whichever way this particular clause goes.

What a State Novel Food Consultancy Actually Sells

A state novel food consultancy sells a defensible file. The core product is an ingredient dossier covering identity of the substance, manufacturing controls, impurity profile, toxicology literature and intake assumptions. The model is borrowed from EU novel food applications and FDA GRAS submissions, adapted to whatever a given state will actually read.

Around that core sit supporting services:

• State product registration, where a state has a registry.
• Label and claims review, since claims are where FDA warning letters tend to land.
• Certificate of analysis auditing, to catch labs that report flattering numbers.
• Third-party lab selection and ongoing oversight.

Candidate states to research one by one are California (AB 45 and AB 8), Texas, Florida and New York. For Texas, I recall that SB 3 was vetoed in 2025, so check for later DSHS rules and any executive action. Verify the current content of every one of these on the state legislature or health department site.

Be plain about the premise. Most states do not have a formal novel food approval process today. Part of this opportunity is a bet that more will create one, and that is open speculation. Today the work is closer to registration support and compliance mapping than to approvals.

Revenue comes in three forms, and they behave differently:

1. Project fees for building a dossier, lumpy but high margin.
2. Retainers for monitoring rule changes and updating labels, steadier and the real base of a business.
3. Expert-witness or regulator-liaison work, rare, reputation-driven and only available once you are trusted by the people on the other side of the table.

A firm that leans on the first alone will have a feast-or-famine year. The retainer line is what turns a sharp consultant into a company.

Precedents: When States and Consultants Filled Federal Silence

Start with the documented precedents abroad. The EU classified CBD extracts as novel foods in January 2019, which meant products needed authorization before sale. A cottage industry of dossier preparers grew around the pending applications. Verify the current status of EFSA reviews before citing outcomes, because that picture has been slow to resolve.

The UK Food Standards Agency set a validation deadline of March 2021 and later published a list of products allowed to remain on sale while applications proceeded. It has also issued daily intake advice. Check the FSA's current numbers and wording before quoting them.

The closest US precedent is food additives. California passed AB 418 in 2023, moving ahead of FDA on specific additives, and other states followed with their own ingredient laws. States will legislate food chemistry when the federal agency lags. That is documented, and it is the strongest piece of evidence for the thesis.

The reasoned extrapolation is this. If the pattern repeats for CBD, a handful of early-mover states set de facto standards and others copy them. Manufacturers, who dislike making fifty versions of a product, then tend to build to the strictest common denominator. That is how state additive rules ended up shaping national formulations.

Now the counter-case, and it is a serious one. EU and UK approvals have been slow and expensive. If regulators never actually approve anything, a consultancy can spend years preparing files that produce no billable outcome and no happy client. Dossier work is only valuable when a door exists at the end of it.

The lesson is to sell the preparation, not the approval. Clients should pay for rigor and readiness that hold value under any regulator, and the pricing should not depend on a regulator's calendar.

Modeling the Opportunity Without Inventing Numbers

I am not going to quote a CBD market size, growth rate or funding total. None of those figures is established here, and a number pulled from memory would only dress up a guess. If you need one for a pitch deck, source it fresh and cite it.

The customer base can be described qualitatively. Likely buyers include:

• Beverage makers like the founder in the opening.
• Edibles brands.
• Topical and pet product companies.
• Ingredient suppliers who need a defensible dossier to sell to brand customers.

Suppliers may be the best clients. One dossier can support many downstream buyers, which spreads the cost and makes the file a sales asset.

The model rests on assumptions you should state out loud and then test:

• How many states create a real pathway, which could be zero, a few or many.
• How many brands will pay for a dossier versus gamble that enforcement stays light.
• What a typical engagement covers, for example one ingredient, one state and one label review.

Change any of those and the economics move a lot. Small brands under cash pressure often choose to ignore enforcement until a letter arrives.

The risks are plain. Federal preemption could erase a state niche overnight. A patchwork might be too costly for small brands to bother with. Professional liability is a genuine exposure if a client is later cited after relying on your file. And dependence on a few lab partners concentrates risk in places you do not control.

A lean entry follows from that. Start in one or two states with clear rules, publish your methodology so clients can judge it, and never promise an approval that a regulator controls. Credibility is the product, and overpromising burns it fastest.

Three Scenarios for the Next Three to Seven Years

Three scenarios cover most of the range for the next three to seven years. None is a prediction.

Scenario one: a federal framework passes. Consultancies pivot to FDA-facing dossiers, and the state niche narrows, although the expertise transfers. Reasoning from precedent means checking how federal action on other ingredients displaced state patchworks, and I have not verified a specific example, so I will not name one here. Treat the displacement pattern as plausible but unconfirmed.

Scenario two: prolonged gridlock. The state patchwork deepens, and demand for state-specific compliance grows. This is the base case the thesis relies on. It is a judgment, not a certainty, and it fails if Congress acts.

Scenario three: a restrictive federal turn. Broad cannabinoid limits shrink the addressable market, and only low-dose CBD or narrowly defined products survive. Demand for advice would stay, but for a much smaller set of clients.

The signals to track are concrete:

• FDA CBD dockets on regulations.gov and notices in the Federal Register.
• Bill actions on congress.gov, especially anything touching the hemp definition or its effective date.
• State health department rulemaking notices.

Who disagrees? Industry groups largely favor a federal framework, which cuts against the state-first thesis. Many state regulators would rather enforce than approve, since an approval pathway creates staff burden and liability. A state approval route may simply never appear, and a candid consultant should plan for that.

The durable asset in this business is regulatory fluency, not any one state law. Laws get delayed, vetoed, preempted and rewritten. A team that can read a statute, build a toxicology file and explain both to a nervous founder can move to whichever scenario arrives. The strongest firms will be built to survive all three.

One last note on evidence. Every 2025-2026 specific in this piece, from the hemp redefinition and its timing to the state bills and rules, is a lead to confirm, not a finding. Anyone acting on it should check congress.gov, fda.gov, regulations.gov and the state agency sites first.

Browse our seed collection.